Ziccum AB (publ) (ZICC.ST)
SEK 0.25
(0.0%)
SEK 0.25
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -21.41 Million SEK | 24.75% |
| 2022 | -28.45 Million SEK | -34.5% |
| 2021 | -21.15 Million SEK | -21.99% |
| 2020 | -17.34 Million SEK | -98.77% |
| 2019 | -8.72 Million SEK | -90.88% |
| 2018 | -4.57 Million SEK | -781.3% |
| 2017 | -518.66 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -5.88 Million SEK | 23.02% |
| 2024 Q1 | -3.95 Million SEK | 48.54% |
| 2024 Q2 | -7.64 Million SEK | -93.2% |
| 2023 FY | -21.41 Million SEK | 24.75% |
| 2023 Q3 | -3.88 Million SEK | 20.29% |
| 2023 Q2 | -4.87 Million SEK | -1.29% |
| 2023 Q1 | -4.8 Million SEK | 39.36% |
| 2023 Q4 | -7.69 Million SEK | -98.15% |
| 2022 Q1 | -6.17 Million SEK | 3.58% |
| 2022 FY | -28.45 Million SEK | -34.5% |
| 2022 Q4 | -7.92 Million SEK | -22.95% |
| 2022 Q3 | -6.44 Million SEK | 18.37% |
| 2022 Q2 | -7.9 Million SEK | -27.94% |
| 2021 Q4 | -6.4 Million SEK | -26.99% |
| 2021 Q3 | -5.04 Million SEK | 3.54% |
| 2021 Q2 | -5.22 Million SEK | -18.39% |
| 2021 Q1 | -4.41 Million SEK | -35.71% |
| 2021 FY | -21.15 Million SEK | -21.99% |
| 2020 FY | -17.34 Million SEK | -98.77% |
| 2020 Q3 | -5.34 Million SEK | -13.53% |
| 2020 Q4 | -3.25 Million SEK | 39.13% |
| 2020 Q2 | -4.7 Million SEK | -18.32% |
| 2020 Q1 | -3.98 Million SEK | -18.98% |
| 2019 Q4 | -3.34 Million SEK | -142.39% |
| 2019 Q3 | -1.38 Million SEK | 39.9% |
| 2019 Q2 | -2.29 Million SEK | -35.94% |
| 2019 Q1 | -1.68 Million SEK | 4.47% |
| 2019 FY | -8.72 Million SEK | -90.88% |
| 2018 Q1 | -141 Thousand SEK | 18.97% |
| 2018 Q2 | -723 Thousand SEK | -412.77% |
| 2018 FY | -4.57 Million SEK | -781.3% |
| 2018 Q4 | -1.76 Million SEK | 4.38% |
| 2018 Q3 | -1.84 Million SEK | -155.74% |
| 2017 Q2 | -112 Thousand SEK | 0.0% |
| 2017 FY | -518.66 Thousand SEK | 0.0% |
| 2017 Q4 | -174 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Active Biotech AB (publ) | -45.8 Million SEK | 53.249% |
| Biovica International AB (publ) | -124.82 Million SEK | 82.846% |
| Cantargia AB (publ) | -280.02 Million SEK | 92.354% |
| CombiGene AB (publ) | -35.66 Million SEK | 39.964% |
| Cyxone AB (publ) | -22.98 Million SEK | 6.86% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -83.353% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -30.577% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 76.574% |
| Fluicell AB (publ) | -26.55 Million SEK | 19.364% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 82.601% |
| Mendus AB (publ) | -101.61 Million SEK | 78.929% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 42.241% |
| I-Tech AB | 20.2 Million SEK | 205.984% |
| Intervacc AB (publ) | -102.85 Million SEK | 79.182% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -76.55% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 275.955% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -19.64% |
| OncoZenge AB (publ) | -15.9 Million SEK | -34.65% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -4788.584% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 94.484% |
| Lipum AB (publ) | -37.17 Million SEK | 42.407% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 91.386% |
| BioArctic AB (publ) | 229.24 Million SEK | 109.34% |
| Genovis AB (publ.) | 61.5 Million SEK | 134.816% |
| Camurus AB (publ) | 431.44 Million SEK | 104.963% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 87.96% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 62.317% |
| Aptahem AB (publ) | -11.11 Million SEK | -92.678% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 93.114% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 88.082% |
| Kancera AB (publ) | -64.88 Million SEK | 67.002% |
| Saniona AB (publ) | -95.81 Million SEK | 77.652% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 49.288% |
| AcouSort AB (publ) | -17.08 Million SEK | -25.297% |
| Xintela AB (publ) | -54.08 Million SEK | 60.409% |
| Abliva AB (publ) | -95.5 Million SEK | 77.581% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 497.549% |
| Amniotics AB (publ) | -30.87 Million SEK | 30.638% |
| 2cureX AB (publ) | -32.51 Million SEK | 34.153% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -66.916% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 95.407% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 97.426% |
| Biosergen AB | -27.03 Million SEK | 20.805% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -29.589% |
| Corline Biomedical AB | -1.8 Million SEK | -1083.637% |
| NextCell Pharma AB | -41.95 Million SEK | 48.97% |
| Nanologica AB (publ) | -75.15 Million SEK | 71.51% |
| LIDDS AB (publ) | -40.2 Million SEK | 46.744% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 93.45% |
| BioInvent International AB (publ) | -330.3 Million SEK | 93.517% |
| SynAct Pharma AB | -215.81 Million SEK | 90.078% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 51.396% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | 9.795% |
| Alzinova AB (publ) | -16.48 Million SEK | -29.927% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 80.408% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 91.405% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -115.629% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 81.105% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -1.522% |
| Simris Alg AB (publ) | -37.3 Million SEK | 42.603% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 85.899% |